For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient ...

OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...

Weill Cornell Medicine scientists have identified Hodgkin lymphoma cells as immune cells halted midway between B cells and plasma cells, reframing the disease as one of failed development. The ...

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of ...

How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

New research challenges the status quo that cancer treatments are responsible for accelerating the aging process, indicating that cancer itself also plays a role. A team of researchers from Moffitt ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

Rising incidence rates and innovation in immunotherapy drive an 8.66% CAGR from 2026 to 2035.Austin, United States, April 23, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The T-cell Lymphoma ...

What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease, but a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...

Doctors monitor lymphocyte and other blood cell levels to predict how your lymphoma will progress. Low lymphocyte counts may suggest that cancer has spread to your bone marrow, or it can be a side ...